Peter M Voorhees MD

Hematologic Oncology

Professor of Medicine, Wake Forest University School of Medicine, Atrium Health / Levine Cancer, Charlotte, NC

1021 Morehead Medical DrSte ACharlotte, NC 28204
Phone+1 980-442-2000
Fax+1 980-442-5241

Dr. Voorhees is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Voorhees' full profile Already have an account?

Education & Training

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2001 - 2004
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1997 - 2001
University of Michigan Medical SchoolClass of 1997

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NC State Medical License 2001 - 2026
WI State Medical License 1998 - 2001
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2016
CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2016
CMS Meaningful Use Stage 1 Certification WebCIS, UNC Health Care, 2013-2016

Clinical Trials

Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy Start of enrollment: 2008 Aug 01
Completed
Phase 2
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2008 Oct 01
Terminated
Phase 1
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
ACTIVE_NOT_RECRUITING
PHASE3

Publications & Presentations

PubMed

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.
Roberto Mina, Meral Beksac, Paula Rodríguez-Otero, Wenming Chen, María-Victoria Mateos
The New England Journal of Medicine. 2026-06-13
Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab: A Panel C...
Binod Dhakal, Moshe Y Levy, Gilbert Ko, Jinghua He, Nina Kim
Oncology and Therapy. 2026-06-01
Expert Validation of an Artificial Intelligence-Enabled Trial Matching Solution Using Real-World Data From Patients With Cancer.
Jai N Patel, M Cyrus Maher, Victoria Morris, Wei Sha, Melani Terry
JCO Oncology Practice. 2026-06-01

Journal Articles

International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease
Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Thomas S Uldrick..., Blood

Abstracts/Posters

Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Result...
Peter M. Voorhees, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Relapsed/Refractory Multiple Myeloma: Current Treatment and Emerging Approaches
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Ex Vivo Assessment of Tnb-383B, a Bcma-Bispecific Antibody, Against Primary Tumor and Endogenous T Cells from Relapsing Multiple Myeloma Patients
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab ﴾Dara﴿, Bortezomib ﴾V﴿, Lenalidomide ﴾R﴿, and De...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

JnJ Darzalex Faspro Approved by USFDA for High Risk Smoldering Multiple MyelomaNovember 7th, 2025
Smoldering Myeloma Gets First FDA-Approved TherapyNovember 7th, 2025
DARZALEX FASPRO® Is the First and Only Treatment Approved by the U.S. FDA for Patients with High-Risk Smoldering Multiple MyelomaNovember 6th, 2025